Tandon Vishal, Kang Woo Seok, Robbins Tremaan A, Spencer Abigail J, Kim Ernest S, McKenna Michael J, Kujawa Sharon G, Fiering Jason, Pararas Erin E L, Mescher Mark J, Sewell William F, Borenstein Jeffrey T
Department of Otology and Laryngology, Massachusetts Eye and Ear Infirmary and Harvard Medical School, 243 Charles Street, Boston, MA 02139, USA.
Materials Engineering and Microfabrication Directorate, Draper, 555 Technology Square, Cambridge, MA 02139, USA.
Lab Chip. 2016 Mar 7;16(5):829-46. doi: 10.1039/c5lc01396h.
The anatomical and pharmacological inaccessibility of the inner ear is a major challenge in drug-based treatment of auditory disorders. This also makes pharmacokinetic characterization of new drugs with systemic delivery challenging, because efficacy is coupled with how efficiently a drug can reach its target. Direct delivery of drugs to cochlear fluids bypasses pharmacokinetic barriers and helps to minimize systemic toxicity, but anatomical barriers make administration of multiple doses difficult without an automated delivery system. Such a system may be required for hair-cell regeneration treatments, which will likely require timed delivery of several drugs. To address these challenges, we have developed a micropump for controlled, automated inner-ear drug delivery with the ultimate goal of producing a long-term implantable/wearable delivery system. The current pump is designed to be used with a head mount for guinea pigs in preclinical drug characterization experiments. In this system, we have addressed several microfluidic challenges, including maintaining controlled delivery at safe, low flow rates and delivering drug without increasing the volume of fluid in the cochlea. By integrating a drug reservoir and all fluidic components into the microfluidic structure of the pump, we have made the drug delivery system robust compared to previous systems that utilized separate, tubing-connected components. In this study, we characterized the pump's unique infuse-withdraw and on-demand dosing capabilities on the bench and in guinea pig animal models. For the animal experiments, we used DNQX, a glutamate receptor antagonist, as a physiological indicator of drug delivery. DNQX suppresses compound action potentials (CAPs), so we were able to infer the distribution and spreading of the DNQX over time by measuring the changes in CAPs in response to stimuli at several characteristic frequencies.
内耳在解剖学和药理学上难以触及,这是基于药物治疗听觉障碍的一项重大挑战。这也使得通过全身给药对新药进行药代动力学表征具有挑战性,因为疗效与药物到达靶点的效率相关。将药物直接递送至耳蜗液可绕过药代动力学屏障,并有助于将全身毒性降至最低,但解剖学屏障使得在没有自动给药系统的情况下难以进行多剂量给药。对于毛细胞再生治疗可能需要这样一个系统,因为这可能需要定时递送几种药物。为应对这些挑战,我们开发了一种用于可控、自动内耳药物递送的微型泵,最终目标是制造一种长期可植入/可穿戴的递送系统。当前的泵设计用于在临床前药物表征实验中与豚鼠的头戴装置配合使用。在这个系统中,我们解决了几个微流体方面的挑战,包括在安全的低流速下维持可控递送以及在不增加耳蜗内液体体积的情况下递送药物。通过将药物储存器和所有流体组件集成到泵的微流体结构中,与之前使用单独的、通过管道连接组件的系统相比,我们使药物递送系统更加坚固耐用。在本研究中,我们在实验台上以及豚鼠动物模型中对该泵独特的注入 - 抽出和按需给药能力进行了表征。在动物实验中,我们使用谷氨酸受体拮抗剂DNQX作为药物递送的生理指标。DNQX会抑制复合动作电位(CAPs),所以我们能够通过测量在几个特征频率下对刺激做出反应时CAPs的变化来推断DNQX随时间的分布和扩散情况。